Cargando…

Natural products that target macrophages in treating non-alcoholic steatohepatitis

Nonalcoholic steatohepatitis (NASH) is the progressive subtype of non-alcoholic fatty liver disease and potentiates risks for both hepatic and metabolic diseases. Although the pathophysiology of NASH is not completely understood, recent studies have revealed that macrophage activation is a major con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chun-Lin, Zhou, Wen-Jun, Ji, Guang, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235205/ https://www.ncbi.nlm.nih.gov/pubmed/32476782 http://dx.doi.org/10.3748/wjg.v26.i18.2155

Ejemplares similares

Role of macrophage scavenger receptor MSR1 in the progression of non-alcoholic steatohepatitis
por: Sheng, Wei, et al.
Publicado: (2022)

Hepatic Macrophages as Targets for the MSC-Based Cell Therapy in Non-Alcoholic Steatohepatitis
por: Kholodenko, Irina V., et al.
Publicado: (2023)

Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma
por: Ramai, Daryl, et al.
Publicado: (2021)

Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis?
por: Cao, Ying, et al.
Publicado: (2020)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

A Pyridazinone Compound for Effectively Treating Non-alcoholic Steatohepatitis by Targeting THRβ
por: Cheng, Hao, et al.
Publicado: (2022)

Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2020)

Nobiletin Alleviates Non-alcoholic Steatohepatitis in MCD-Induced Mice by Regulating Macrophage Polarization
por: Wang, Si-wei, et al.
Publicado: (2021)

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
por: Lee, Kuei-Chuan, et al.
Publicado: (2023)

Modulating hepatic macrophages with annexin A1 in non-alcoholic steatohepatitis
por: De Ponti, Federico F., et al.
Publicado: (2022)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
por: Habig, Gregory, et al.
Publicado: (2021)

Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis
por: Branković, Marija, et al.
Publicado: (2022)

Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
por: Rios, Rafael S., et al.
Publicado: (2021)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis
por: Povero, Davide, et al.
Publicado: (2016)

Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis
por: Kakehashi, Anna, et al.
Publicado: (2023)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation
por: Shu, Xiangbing, et al.
Publicado: (2021)

Mechanisms of ductular reaction in non-alcoholic steatohepatitis
por: Chen, Yue, et al.
Publicado: (2022)

P2X7 Receptor in Alcoholic Steatohepatitis and Alcoholic Liver Fibrosis
por: Xia, Guo-Qing, et al.
Publicado: (2022)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

Berberine ameliorates non-alcoholic steatohepatitis in ApoE(−/−) mice
por: Yang, Jin, et al.
Publicado: (2017)

Lingguizhugan decoction improves non-alcoholic steatohepatitis partially by modulating gut microbiota and correlated metabolites
por: Zhu, Mingzhe, et al.
Publicado: (2023)

Recent advances in understanding/management of non-alcoholic steatohepatitis
por: Pacana, Tommy, et al.
Publicado: (2015)

Immune cell-mediated features of non-alcoholic steatohepatitis
por: Huby, Thierry, et al.
Publicado: (2021)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Expansion of macrophage and liver sinusoidal endothelial cell subpopulations during non-alcoholic steatohepatitis progression
por: Shen, Zhenyang, et al.
Publicado: (2023)

Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2013)

Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma: Implications for Lycopene Intervention
por: Ip, Blanche C., et al.
Publicado: (2013)

Fetuin-A in Activated Liver Macrophages Is a Key Feature of Non-Alcoholic Steatohepatitis
por: Etienne, Quentin, et al.
Publicado: (2022)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
por: Xu, Xiaohan, et al.
Publicado: (2022)

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma
por: Kumar, Rahul, et al.
Publicado: (2020)

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
por: Dowman, J K, et al.
Publicado: (2011)

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Iravani, Farzaneh, et al.
Publicado: (2018)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis
por: Yang, Zhen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rhljv5polgi1q4vufrf13clcb7